Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 194

1.

Defining Clear Cell Papillary Renal Cell Carcinoma in Routine Clinical Practice.

Gupta S, Inwards CY, Van Dyke DL, Jimenez RE, Cheville JC.

Histopathology. 2020 Jan 27. doi: 10.1111/his.14071. [Epub ahead of print]

PMID:
31989679
2.

The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor.

Wang Y, Rabe KG, Bold MS, Shi M, Hanson CA, Schwager SM, Call TG, Kenderian SS, Muchtar E, Hayman SR, Koehler AB, Fonder AL, Chanan-Khan AA, Van Dyke DL, Slager SL, Kay NE, Ding W, Leis JF, Parikh SA.

Haematologica. 2020 Jan 23. pii: haematol.2019.240564. doi: 10.3324/haematol.2019.240564. [Epub ahead of print] No abstract available.

3.

Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.

Hampel PJ, Call TG, Ding W, Muchtar E, Kenderian SS, Wang Y, Leis JF, Witzig TE, Koehler AB, Fonder AL, Schwager SM, Rabe KG, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA.

Am J Hematol. 2020 Mar;95(3):E57-E60. doi: 10.1002/ajh.25690. Epub 2019 Dec 13. No abstract available.

PMID:
31788844
4.

Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center.

Wang Y, Tschautscher MA, Rabe KG, Call TG, Leis JF, Kenderian SS, Kay NE, Muchtar E, Van Dyke DL, Koehler AB, Schwager SM, Slager SL, Parikh SA, Ding W.

Haematologica. 2020 Mar;105(3):765-773. doi: 10.3324/haematol.2019.224121. Epub 2019 Jun 13.

5.

Warthin-like Mucoepidermoid Carcinoma of the Parotid Gland: Unusual Morphology and Diagnostic Pitfalls.

Zhang D, Liao X, Tang Y, Meyer RG, VAN Dyke DL, Liu X, Islam MN, Lai J.

Anticancer Res. 2019 Jun;39(6):3213-3217. doi: 10.21873/anticanres.13461. Review.

PMID:
31177170
6.

Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations.

Peterson JF, Rowsey RA, Marcou CA, Pearce KE, Williamson CM, Frederick LA, Greipp PT, Ketterling RP, Kumar S, Viswanatha DS, Polley MY, Fink JM, Reichard KK, Van Dyke DL, Baughn LB.

Blood Cancer J. 2019 Feb 19;9(3):20. doi: 10.1038/s41408-019-0182-z. No abstract available.

7.

IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes.

Fang H, Reichard KK, Rabe KG, Hanson CA, Call TG, Ding W, Kenderian SS, Muchtar E, Schwager SM, Leis JF, Chanan-Khan AA, Slager SL, Braggio E, Smoley SA, Kay NE, Shanafelt TD, Van Dyke DL, Parikh SA.

Am J Hematol. 2019 Mar;94(3):338-345. doi: 10.1002/ajh.25385. Epub 2019 Jan 8.

8.

Assessing copy number aberrations and copy-neutral loss-of-heterozygosity across the genome as best practice: An evidence-based review from the Cancer Genomics Consortium (CGC) working group for chronic lymphocytic leukemia.

Chun K, Wenger GD, Chaubey A, Dash DP, Kanagal-Shamanna R, Kantarci S, Kolhe R, Van Dyke DL, Wang L, Wolff DJ, Miron PM.

Cancer Genet. 2018 Dec;228-229:236-250. doi: 10.1016/j.cancergen.2018.07.004. Epub 2018 Oct 16. Review.

PMID:
30554732
9.

Analysis of Common Abnormalities Seen in Chronic Lymphocytic Leukemia Using Fluorescence In Situ Hybridization.

Meyer RG, Van Dyke DL.

Methods Mol Biol. 2019;1881:35-49. doi: 10.1007/978-1-4939-8876-1_4.

PMID:
30350196
10.

Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia.

Aypar U, Smoley SA, Pitel BA, Pearce KE, Zenka RM, Vasmatzis G, Johnson SH, Smadbeck JB, Peterson JF, Geiersbach KB, Van Dyke DL, Thorland EC, Jenkins RB, Ketterling RP, Greipp PT, Kearney HM, Hoppman NL, Baughn LB.

Eur J Haematol. 2019 Jan;102(1):87-96. doi: 10.1111/ejh.13179. Epub 2018 Nov 22.

PMID:
30270457
11.

Multiple isodicentric Y chromosomes in myeloid malignancies: a unique cytogenetic entity and potential therapeutic target.

Mangaonkar AA, Patnaik MM, Oliver GR, Rao KW, Kaiser-Rogers K, Davila JI, Fadra N, Wehrs RN, Elliott MA, Greipp PT, Halling KC, Van Dyke DL.

Leuk Lymphoma. 2019 Mar;60(3):821-824. doi: 10.1080/10428194.2018.1498492. Epub 2018 Aug 30. No abstract available.

PMID:
30160574
12.

The Utilization of Chromosomal Microarray Technologies for Hematologic Neoplasms: An ACLPS Critical Review.

Peterson JF, Van Dyke DL, Hoppman NL, Kearney HM, Sukov WR, Greipp PT, Ketterling RP, Baughn LB.

Am J Clin Pathol. 2018 Oct 1;150(5):375-384. doi: 10.1093/ajcp/aqy076. Review.

PMID:
30052716
13.

A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow: A Single Institutional Experience.

Fang H, Ketterling RP, Hanson CA, Pardanani A, Kurtin PJ, Chen D, Greipp PT, Howard MT, King RL, Van Dyke DL, Reichard KK.

Am J Clin Pathol. 2018 Oct 1;150(5):421-431. doi: 10.1093/ajcp/aqy064.

PMID:
30032299
14.

A rapid and reliable chromosome analysis method for products of conception using interphase nuclei.

Babu R, Van Dyke DL, Bhattacharya S, Dev VG, Liu M, Kwon M, Gu G, Koduru P, Rao N, Williamson C, Fuentes E, Fuentes S, Papa S, Kopuri S, Lal V.

Mol Genet Genomic Med. 2018 May;6(3):370-381. doi: 10.1002/mgg3.381. Epub 2018 Mar 24.

15.

Low-grade fibromyxoid sarcoma arising within the median nerve.

Swanson AA, Giannini C, Folpe AL, Van Dyke DL, Amrami KK, Michalak WA, Vaubel RA.

Neuropathology. 2018 Jun;38(3):309-314. doi: 10.1111/neup.12453. Epub 2018 Jan 3.

PMID:
29314300
16.

Interphase Chromosome Profiling: A Method for Conventional Banded Chromosome Analysis Using Interphase Nuclei.

Babu R, Van Dyke DL, Dev VG, Koduru P, Rao N, Mitter NS, Liu M, Fuentes E, Fuentes S, Papa S.

Arch Pathol Lab Med. 2018 Feb;142(2):213-228. doi: 10.5858/arpa.2016-0621-OA. Epub 2017 Oct 5.

PMID:
28981371
17.

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, Shanafelt TD, Sinha S, Le-Rademacher J, Feldman AL, Habermann TM, Witzig TE, Wiseman GA, Lin Y, Asmus E, Nowakowski GS, Conte MJ, Bowen DA, Aitken CN, Van Dyke DL, Greipp PT, Liu X, Wu X, Zhang H, Secreto CR, Tian S, Braggio E, Wellik LE, Micallef I, Viswanatha DS, Yan H, Chanan-Khan AA, Kay NE, Dong H, Ansell SM.

Blood. 2017 Jun 29;129(26):3419-3427. doi: 10.1182/blood-2017-02-765685. Epub 2017 Apr 19.

18.

Commentary on the decision of the American Board of Medical Genetics and Genomics to create a 24-month specialty of Laboratory Genetics and Genomics.

Bieber FR, Cherry AM, Emanuel BS, Francke U, Hoyme HE, Jackson LG, Morton CC, Muenke M, Powell CM, Punnett HH, Rao PN, Schwartz S, Stevenson RE, Van Dyke DL.

Genet Med. 2017 Mar;19(3):294-296. doi: 10.1038/gim.2016.171. Epub 2016 Nov 17. Erratum in: Genet Med. 2017 Apr;19(4):483.

PMID:
27854359
19.

Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome.

Barrio S, Shanafelt TD, Ojha J, Chaffee KG, Secreto C, Kortüm KM, Pathangey S, Van-Dyke DL, Slager SL, Fonseca R, Kay NE, Braggio E.

Leukemia. 2017 Jan;31(1):170-176. doi: 10.1038/leu.2016.172. Epub 2016 Jun 14.

20.

Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization:  Defining an Effective Utilization Strategy for Evaluation of Myelodysplastic Syndromes.

He R, Wiktor AE, Durnick DK, Kurtin PJ, Van Dyke DL, Tefferi A, Patnaik MS, Ketterling RP, Hanson CA.

Am J Clin Pathol. 2016 Jul;146(1):86-94. doi: 10.1093/ajcp/aqw077. Epub 2016 Jun 27.

PMID:
27353768
21.

Is It Time for a New Gold Standard? FISH vs Cytogenetics in AML Diagnosis.

Hammer RD, Doll D, Layfield L, He R, Reichard KK, Hanson CA, Kurtin PJ, Howard MT, Litzow MR, Van Dyke DL, Ketterling RP, Wiktor AE.

Am J Clin Pathol. 2016 Mar;145(3):430-2. doi: 10.1093/ajcp/aqw008. No abstract available.

PMID:
27124927
22.

The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience.

Van Dyke DL, Werner L, Rassenti LZ, Neuberg D, Ghia E, Heerema NA, Dal Cin P, Dell Aquila M, Sreekantaiah C, Greaves AW, Kipps TJ, Kay NE.

Br J Haematol. 2016 Apr;173(1):105-13. doi: 10.1111/bjh.13933. Epub 2016 Feb 5.

23.

Conventional karyotyping and fluorescence in situ hybridization: an effective utilization strategy in diagnostic adult acute myeloid leukemia.

He R, Wiktor AE, Hanson CA, Ketterling RP, Kurtin PJ, Van Dyke DL, Litzow MR, Howard MT, Reichard KK.

Am J Clin Pathol. 2015 Jun;143(6):873-8. doi: 10.1309/AJCPP6LVMQG4LNCK. Erratum in: Am J Clin Pathol. 2015 Jul;144(1):175. Howard, Matthew H [corrected to Howard, Matthew T].

PMID:
25972330
24.

Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes.

Parikh SA, Leis JF, Chaffee KG, Call TG, Hanson CA, Ding W, Chanan-Khan AA, Bowen D, Conte M, Schwager S, Slager SL, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD.

Cancer. 2015 Sep 1;121(17):2883-91. doi: 10.1002/cncr.29438. Epub 2015 Apr 30.

25.

Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia.

Ojha J, Secreto CR, Rabe KG, Van Dyke DL, Kortum KM, Slager SL, Shanafelt TD, Fonseca R, Kay NE, Braggio E.

Br J Haematol. 2015 May;169(3):445-8. doi: 10.1111/bjh.13211. Epub 2014 Nov 10. No abstract available.

26.

Isolated trisomy 2 in bone marrows of patients with suspected hematopoietic malignancies.

Aypar U, Reichard KK, Waltman LA, Van Dyke DL.

Cancer Genet. 2014 Apr;207(4):124-7. doi: 10.1016/j.cancergen.2014.02.011. Epub 2014 Mar 4.

PMID:
24736057
27.

Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis.

Greipp PT, Smoley SA, Viswanatha DS, Frederick LS, Rabe KG, Sharma RG, Slager SL, Van Dyke DL, Shanafelt TD, Tschumper RC, Zent CS.

Br J Haematol. 2013 Nov;163(3):326-33. doi: 10.1111/bjh.12534. Epub 2013 Aug 27.

28.

Subjectivity in chromosome band-level estimation: a multicenter study.

Geiersbach KB, Gardiner AE, Wilson A, Shetty S, Bruyère H, Zabawski J, Saxe DF, Gaulin R, Williamson C, Van Dyke DL.

Genet Med. 2014 Feb;16(2):170-5. doi: 10.1038/gim.2013.95. Epub 2013 Jul 25.

PMID:
23887773
29.

Long QT syndrome-associated mutations in intrauterine fetal death.

Crotti L, Tester DJ, White WM, Bartos DC, Insolia R, Besana A, Kunic JD, Will ML, Velasco EJ, Bair JJ, Ghidoni A, Cetin I, Van Dyke DL, Wick MJ, Brost B, Delisle BP, Facchinetti F, George AL, Schwartz PJ, Ackerman MJ.

JAMA. 2013 Apr 10;309(14):1473-82. doi: 10.1001/jama.2013.3219.

30.

Advanced maternal age in polyploidy with concurrent aneuploidy.

Waltman LA, Eckel-Passow JE, Sharma RG, Van Dyke DL.

Am J Med Genet A. 2013 May;161A(5):1200-2. doi: 10.1002/ajmg.a.35870. Epub 2013 Mar 29. No abstract available.

PMID:
23554063
31.

When are apparently non-clonal abnormalities in bone marrow chromosome studies actually clonal?

Hutchens C, Ketterling RP, Van Dyke DL.

Cancer Genet. 2012 Jul-Aug;205(7-8):405-9. doi: 10.1016/j.cancergen.2012.04.003.

PMID:
22868001
32.

Leukemia risk models in primary myelofibrosis: an International Working Group study.

Tefferi A, Pardanani A, Gangat N, Begna KH, Hanson CA, Van Dyke DL, Caramazza D, Vannucchi AM, Morra E, Cazzola M, Pereira A, Cervantes F, Passamonti F.

Leukemia. 2012 Jun;26(6):1439-41. doi: 10.1038/leu.2011.374. Epub 2012 Jan 13. No abstract available.

PMID:
22289985
33.

Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse.

Braggio E, Kay NE, VanWier S, Tschumper RC, Smoley S, Eckel-Passow JE, Sassoon T, Barrett M, Van Dyke DL, Byrd JC, Jelinek DF, Shanafelt TD, Fonseca R.

Leukemia. 2012 Jul;26(7):1698-701. doi: 10.1038/leu.2012.14. Epub 2012 Jan 20. No abstract available.

34.

Clinical diagnostic testing for the cytogenetic and molecular causes of male infertility: the Mayo Clinic experience.

Hofherr SE, Wiktor AE, Kipp BR, Dawson DB, Van Dyke DL.

J Assist Reprod Genet. 2011 Nov;28(11):1091-8. doi: 10.1007/s10815-011-9633-6. Epub 2011 Sep 13.

35.

Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients.

Tefferi A, Jimma T, Gangat N, Vaidya R, Begna KH, Hanson CA, Van Dyke DL, Caramazza D, Pardanani A.

Blood. 2011 Oct 27;118(17):4595-8. doi: 10.1182/blood-2011-08-371096. Epub 2011 Aug 31.

PMID:
21881047
36.

The significance of isolated Y chromosome loss in bone marrow metaphase cells from males over age 50 years.

Wiktor AE, Van Dyke DL, Hodnefield JM, Eckel-Passow J, Hanson CA.

Leuk Res. 2011 Oct;35(10):1297-300. doi: 10.1016/j.leukres.2011.05.002. Epub 2011 Jun 23.

PMID:
21703685
37.

College of American Pathologists/American College of Medical Genetics proficiency testing for constitutional cytogenomic microarray analysis.

Brothman AR, Dolan MM, Goodman BK, Park JP, Persons DL, Saxe DF, Tepperberg JH, Tsuchiya KD, Van Dyke DL, Wilson KS, Wolff DJ, Theil KS.

Genet Med. 2011 Sep;13(9):765-9. doi: 10.1097/GIM.0b013e31821d3165.

PMID:
21633292
38.

Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival.

Vaidya R, Caramazza D, Begna KH, Gangat N, Van Dyke DL, Hanson CA, Pardanani A, Tefferi A.

Blood. 2011 May 26;117(21):5612-5. doi: 10.1182/blood-2010-11-320002. Epub 2011 Mar 30.

PMID:
21450904
39.

Applying Toyota production system techniques for medication delivery: improving hospital safety and efficiency.

Newell TL, Steinmetz-Malato LL, Van Dyke DL.

J Healthc Qual. 2011 Mar-Apr;33(2):15-22. doi: 10.1111/j.1945-1474.2010.00104.x.

PMID:
21385276
40.

Biological evaluation of CpG stimulation of normal human B-cells: implications for B-cell biology and cytogenetic analysis of CLL B-cells.

Wu X, Smoley SA, Peterson MA, Walters DK, Arendt BK, Nowakowski GS, Van Dyke DL, Kay NE, Jelinek DF.

Br J Haematol. 2011 May;153(3):402-5. doi: 10.1111/j.1365-2141.2010.08514.x. Epub 2011 Feb 17. No abstract available.

41.

Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy.

Kay NE, Eckel-Passow JE, Braggio E, Vanwier S, Shanafelt TD, Van Dyke DL, Jelinek DF, Tschumper RC, Kipps T, Byrd JC, Fonseca R.

Cancer Genet Cytogenet. 2010 Dec;203(2):161-8. doi: 10.1016/j.cancergencyto.2010.09.003.

42.

Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium.

Smoley SA, Van Dyke DL, Kay NE, Heerema NA, Dell' Aquila ML, Dal Cin P, Koduru P, Aviram A, Rassenti L, Byrd JC, Rai KR, Brown JR, Greaves AW, Eckel-Passow J, Neuberg D, Kipps TJ, Dewald GW.

Cancer Genet Cytogenet. 2010 Dec;203(2):141-8. doi: 10.1016/j.cancergencyto.2010.08.009.

43.

Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study.

Heerema NA, Byrd JC, Dal Cin PS, Dell' Aquila ML, Koduru PR, Aviram A, Smoley SA, Rassenti LZ, Greaves AW, Brown JR, Rai KR, Kipps TJ, Kay NE, Van Dyke DL; Chronic Lymphocytic Leukemia Research Consortium.

Cancer Genet Cytogenet. 2010 Dec;203(2):134-40. doi: 10.1016/j.cancergencyto.2010.07.128.

44.

Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype.

Patnaik MM, Hanson CA, Hodnefield JM, Knudson R, Van Dyke DL, Tefferi A.

Leukemia. 2011 Feb;25(2):266-70. doi: 10.1038/leu.2010.258. Epub 2010 Nov 12.

PMID:
21072042
45.

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.

Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke DL, Hanson C, Pardanani A, Tefferi A.

Leukemia. 2011 Jan;25(1):82-8. doi: 10.1038/leu.2010.234. Epub 2010 Oct 14.

46.

Nearly identical near-haploid karyotype in a peritoneal mesothelioma and a retroperitoneal malignant peripheral nerve sheath tumor.

Sukov WR, Ketterling RP, Wei S, Monaghan K, Blunden P, Mazzara P, Raghavan R, Oliviera AM, Wiktor AE, Keeney GL, Van Dyke DL.

Cancer Genet Cytogenet. 2010 Oct 15;202(2):123-8. doi: 10.1016/j.cancergencyto.2010.07.120.

PMID:
20875874
47.

Detection of recurrent chromosomal defects in chronic lymphocytic leukemia/small lymphocytic lymphoma: innovations and applications.

Zent CS, Van Dyke DL.

Leuk Lymphoma. 2010 Feb;51(2):186-7. doi: 10.3109/10428190903580436. No abstract available.

PMID:
20109070
48.

Laboratory guideline for Turner syndrome.

Wolff DJ, Van Dyke DL, Powell CM; Working Group of the ACMG Laboratory Quality Assurance Committee.

Genet Med. 2010 Jan;12(1):52-5. doi: 10.1097/GIM.0b013e3181c684b2. Erratum in: Genet Med. 2012 Feb;14(2):281.

PMID:
20081420
49.

Double trisomy revisited--a multicenter experience.

Micale M, Insko J, Ebrahim SA, Adeyinka A, Runke C, Van Dyke DL.

Prenat Diagn. 2010 Feb;30(2):173-6. doi: 10.1002/pd.2429. No abstract available.

PMID:
20041396
50.

Dosage regulation of the active X chromosome in human triploid cells.

Deng X, Nguyen DK, Hansen RS, Van Dyke DL, Gartler SM, Disteche CM.

PLoS Genet. 2009 Dec;5(12):e1000751. doi: 10.1371/journal.pgen.1000751. Epub 2009 Dec 4.

Supplemental Content

Loading ...
Support Center